Fortune 500
MerckRANK69
The pharma giant had a banner year in 2019, climbing seven slots on the Fortune 500. Revenue rose almost 11%, to $46.8 billion, while profits leaped 58%, to $9.8 billion. Blockbuster cancer drug Keytruda, as well as an expanded line of animal medicines, have helped power Merck’s growth—though its share price has not seen as much of a lift as some competitors'. More recently, Merck has been notably quiet in medical chatter about the novel coronavirus. But executives on a late April earnings call announced that the company has teams scanning its portfolio of antiviral candidates and vaccine assets for potential treatments.
Brendan McDermid—REUTERS
Lists ranking Merck
RANK100
100 Best Companies to Work For - 2021Our 2021 list of the 100 best companies to work fo...view in list
RANK9
20 Best Workplaces in Biotechnology and Pharmaceuticals - 2021The best U.S. biotechnology and pharmaceutical com...view in list
RANK37*
World’s Most Admired Companies - 2021After a year in which humanity leaned more heavily...view in list
Latest news for Merck
- LeadershipHow Abbott, Merck, and more health care and biopharma companies took care during COVIDMarch 12, 2021 12:00 PM UTC
- HealthBiden set to announce vaccine manufacturing partnership between Merck and Johnson & JohnsonMarch 2, 2021 9:57 PM UTC
- HealthMerck ends development of two COVID-19 vaccines after weak trial resultsJanuary 25, 2021 12:06 PM UTC
- FinanceWarren Buffett is going all in on the vaccine rally, piling into these stocksNovember 17, 2020 10:55 AM UTC
- HealthOxford’s COVID vaccine deal with AstraZeneca raises concerns about access and pricingAugust 24, 2020 9:00 AM UTC